These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27765859)

  • 21. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.
    Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA
    J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
    Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
    JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.
    Coakeley S; Cho SS; Koshimori Y; Rusjan P; Harris M; Ghadery C; Kim J; Lang AE; Wilson A; Houle S; Strafella AP
    J Cereb Blood Flow Metab; 2017 Sep; 37(9):3150-3160. PubMed ID: 28155586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [
    Whitwell JL; Lowe VJ; Tosakulwong N; Weigand SD; Senjem ML; Schwarz CG; Spychalla AJ; Petersen RC; Jack CR; Josephs KA
    Mov Disord; 2017 Jan; 32(1):124-133. PubMed ID: 27787958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [
    Jonasson M; Wall A; Chiotis K; Leuzy A; Eriksson J; Antoni G; Nordberg A; Lubberink M
    Neuroimage Clin; 2019; 22():101681. PubMed ID: 30710871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand.
    Cselényi Z; Jönhagen ME; Forsberg A; Halldin C; Julin P; Schou M; Johnström P; Varnäs K; Svensson S; Farde L
    J Nucl Med; 2012 Mar; 53(3):415-24. PubMed ID: 22323782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of [
    Baker SL; Provost K; Thomas W; Whitman AJ; Janabi M; Schmidt ME; Timmers M; Kolb HC; Rabinovici GD; Jagust WJ
    J Cereb Blood Flow Metab; 2021 Dec; 41(12):3302-3313. PubMed ID: 34259071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [
    Lagarde J; Olivieri P; Caillé F; Gervais P; Baron JC; Bottlaender M; Sarazin M
    J Neurol; 2019 Dec; 266(12):3087-3097. PubMed ID: 31535269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PET Quantification of Tau Pathology in Human Brain with 11C-PBB3.
    Kimura Y; Ichise M; Ito H; Shimada H; Ikoma Y; Seki C; Takano H; Kitamura S; Shinotoh H; Kawamura K; Zhang MR; Sahara N; Suhara T; Higuchi M
    J Nucl Med; 2015 Sep; 56(9):1359-65. PubMed ID: 26182966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
    Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with
    Tagai K; Ikoma Y; Endo H; Debnath OB; Seki C; Matsuoka K; Matsumoto H; Oya M; Hirata K; Shinotoh H; Takahata K; Kurose S; Sano Y; Ono M; Shimada H; Kawamura K; Zhang MR; Takado Y; Higuchi M
    Neuroimage; 2022 Dec; 264():119763. PubMed ID: 36427751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of [
    Meindl M; Zatcepin A; Gnörich J; Scheifele M; Zaganjori M; Groß M; Lindner S; Schaefer R; Simmet M; Roemer S; Katzdobler S; Levin J; Höglinger G; Bischof AC; Barthel H; Sabri O; Bartenstein P; Saller T; Franzmeier N; Ziegler S; Brendel M
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3252-3266. PubMed ID: 38717592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evaluation of [
    Schmidt ME; Janssens L; Moechars D; Rombouts FJR; Timmers M; Barret O; Constantinescu CC; Madonia J; Russell DS; Sandiego CM; Kolb H
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3176-3185. PubMed ID: 32535652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of the Semiquantitative Static SUVR Method for
    Ottoy J; Verhaeghe J; Niemantsverdriet E; Wyffels L; Somers C; De Roeck E; Struyfs H; Soetewey F; Deleye S; Van den Bossche T; Van Mossevelde S; Ceyssens S; Versijpt J; Stroobants S; Engelborghs S; Staelens S
    J Nucl Med; 2017 Sep; 58(9):1483-1489. PubMed ID: 28336779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Head to head comparison of [
    Jang YK; Lyoo CH; Park S; Oh SJ; Cho H; Oh M; Ryu YH; Choi JY; Rabinovici GD; Kim HJ; Moon SH; Jang H; Lee JS; Jagust WJ; Na DL; Kim JS; Seo SW
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):432-442. PubMed ID: 29143870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
    Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
    J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [
    de Vries BM; Timmers T; Wolters EE; Ossenkoppele R; Verfaillie SCJ; Schuit RC; Scheltens P; van der Flier WM; Windhorst AD; van Berckel BNM; Boellaard R; Golla SSV
    Mol Imaging Biol; 2021 Aug; 23(4):550-559. PubMed ID: 33443720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.
    Lopresti BJ; Klunk WE; Mathis CA; Hoge JA; Ziolko SK; Lu X; Meltzer CC; Schimmel K; Tsopelas ND; DeKosky ST; Price JC
    J Nucl Med; 2005 Dec; 46(12):1959-72. PubMed ID: 16330558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans.
    Nye JA; Votaw JR; Bremner JD; Davis MR; Voll RJ; Camp VM; Goodman MM
    Nucl Med Biol; 2014 Mar; 41(3):217-22. PubMed ID: 24533985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoamine oxidase B inhibitor, selegiline, reduces
    Ng KP; Pascoal TA; Mathotaarachchi S; Therriault J; Kang MS; Shin M; Guiot MC; Guo Q; Harada R; Comley RA; Massarweh G; Soucy JP; Okamura N; Gauthier S; Rosa-Neto P
    Alzheimers Res Ther; 2017 Mar; 9(1):25. PubMed ID: 28359327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.